12:00 AM
 | 
Jun 08, 2015
 |  BC Week In Review  |  Clinical News  |  Clinical Status

BIOD-531: Phase IIb started

Biodel began the open-label, U.S. Phase IIb Study 3-250 to compare twice daily subcutaneous BIOD-531 vs. Humalog Mix 75/25 insulin lispro...

Read the full 85 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >